No items found.
Dr. Pavol Cekan, CEO of MultiplexDX, became one of the distinguished speakers during the 0100 Conference in Vienna, Austria on March 14th 2019. From a geographical perspective, Vienna holds special significance as the city where Western and Eastern investors meet. In general, 0100 Conferences help to explore and expand business opportunities and networks in private markets, bringing together key venture capitals and private equity, private and institutional investors, startups, entrepreneurs and advisors. The conference presents the latest trends and insights in the private equity industry with a market-driven agenda. The organizers prepared an amazing line-up of speakers who shared their wealth of knowledge on topics ranging from “The State of European Private Equity” through “CEOs and VCs Talk to Smart Sourcing”. There were 11 panels and 56 outstanding speakers from all around the world creating an inspiring atmosphere with interactive discussions and case studies.
Dr. Pavol Cekan discussed “New Age Entrepreneurship”, speaking about the role of entrepreneurs in helping to resolve major societal issues. He said:
"Every day when I wake up I am very grateful that I founded a company. I don't think it would be possible to have such an impact working for a large corporation."
The 0100 Conference is a new generation conference company specializing in high-profile, networking meetings for leading players in the venture capital and private equity ecosystem. The conference company organizes several interactive meetings during the year in European capital cities like Vienna, Prague, Dublin, Berlin, Tallinn, Copenhagen, Luxembourg and Bratislava. Their goal is to provide attendees with a knowledge sharing platform and maximize their chance of finding the next venture partner. It is a unique opportunity to meet all the key leaders under a single roof.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.